CClinicalTrials.gg
CompletedNCT03283254PREPPUpdated Sep 26, 2025Results posted

PREPP: Preventing Postpartum Depression

An interventional study of Practical Resources for Effective Postpartum Parenting (PREPP) and Enhanced Treatment As Usual (ETAU) in Postpartum Depression (PPD), sponsored by Columbia University. Completed at 1 site in United States. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-26.

Sponsored by Columbia University · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
216
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Study summary

The primary aim of this study is to determine if a behavioral intervention targeting maternal caregiving of young infants can increase infant sleep and reduce fuss/cry behavior, and thereby (1) reduce the incidence and/or severity of postpartum maternal depression and (2) improve the quality of the mother-infant interaction and subsequent child development. Specifically, the study team will investigate: (1) the effectiveness of the intervention compared to usual care; (2) if the effects of the intervention can be detected in the assessments of the quality of mother-infant interaction; (3) if there are prenatal and/or postnatal biomarkers that can help identify infants whose behavior is more likely to play a role in their mothers' depression; (4) if these markers differentiate which infants will be most responsive to the intervention(s); and (5), if assessments of brain function at birth and at 4-6 weeks of age provide biological nodal points for identifying the effects of the intervention on infant brain development. Participants will be recruited during their 2nd trimester, and will be randomly separated into one of two groups: a group that receives coaching in parenting techniques 3 coaching sessions and 2 check-in sessions or one that receives treatment as usual.

Read the detailed description

Of the nearly 4 million mothers delivering live births each year in the United States, approximately 560,000 - or 14% - will develop major or minor depression within the first four months postpartum, when the rate peaks. This number dwarfs prevalence rates for gestational diabetes (2-5%) and is comparable to preterm birth (11.4%). Postpartum depression (PPD) has substantial consequences: poorer maternal quality of life, significant emotional suffering, and suicide risk. PPD predicts diminished mother-infant bonding, and poor outcomes in social-emotional and, in some groups, cognitive development. PPD is undertreated in part because women are reluctant to seek treatment due to the stigma associated with mental health care, logistical barriers to at-tending added health care appointments, and disinclination to take medications while breastfeeding. Of preventive interventions, few embed services in obstetrical care or leverage the unique mother-infant dyadic orientation of the childbearing period. The investigators developed a novel intervention based on the conceptualization of maternal depression as a potential disorder of the mother-infant dyad, and one that can be approached through psychological and behavioral changes in the mother - commencing before birth - that affect her and the child. PREPP (Practical Resources for Effective Postpartum Parenting) enrolls distressed pregnant women at risk for PPD, spans late pregnancy to the 6 week postpartum check up, comprises four in-person 'coaching' sessions adjunctive to obstetrical (OB) prenatal and postnatal appointments, one phone session, and imparts (a) mindfulness and self-reflection skills, (b) parenting skills, and (c) psycho-education.

02

Conditions studied

  • Postpartum Depression (PPD)

Keywords

  • Postpartum Depression Treatment
03

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  1. Healthy pregnant women between 18-45 years old (based on self report)
  2. A score of ≥19 on the Predictive Index of Postnatal Depression (PIPD), indicating risk for developing postpartum depression or score of ≥7 on the Edinburgh Postnatal Depression Scale
  3. A healthy, singleton pregnancy (based on self report)
  4. English speaking (based on self report)
  5. Receiving standard prenatal care (based on self report)

Exclusion criteria

Exclusion Criteria:

  1. Multi-fetal pregnancy (based on self-report)
  2. Smoking, illicit drug use, or alcohol use during pregnancy (based on self-report)
  3. Acute medical illness or significant pregnancy complication (based on self-report)
  4. Currently in weekly, individual psychotherapy, including psychopharmacology (based on self report)
  5. Psychotic d/o; Bipolar I; Major Depressive d/o (based on M.I.N.I.)
04

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
216 participants (actual)

Study arms

  • Experimental
    Practical Resources for Effective Postpartum (PREPP)

    A psychotherapeutic preventive intervention that involves psychoeducation and cognitive behavioral techniques.

    Behavioral: Practical Resources for Effective Postpartum Parenting (PREPP)

  • Active comparator
    Enhanced Treatment as Usual

    Psychoeducation about Postpartum Depression, referral to treatment in the community and monitoring

    Behavioral: Enhanced Treatment As Usual (ETAU)

Interventions

  • BehavioralPractical Resources for Effective Postpartum Parenting (PREPP)

    A preventive psychotherapy intervention for PPD: Participants in this arm of the study receive PREPP (Practical Resources for Effective Postpartum Parenting). PREPP is a brief preventive intervention for Postpartum Depression that focuses on the birthing parent-infant dyad and consists of 5 sessions that take place during pregnancy through 6 weeks postpartum carried out by study clinicians referred to as 'coaches.' The sessions of this preventive psychotherapy are comprised of three components: (a) mindfulness and self-reflection skills, (b) parenting skills and (c) psycho-education.

    Also known as: PREPP

  • BehavioralEnhanced Treatment As Usual (ETAU)

    Psychoeducation, Clinical Assessment, Potential Referral: Participants receive "usual care" along with Postpartum Depression psychoeducation and enhanced support for finding perinatal mental healthcare treatment when appropriate by meeting with a study clinician specifically assigned to provide ETAU in this study at three times that are aligned with PREPP sessions that span from pregnancy to 6 weeks postpartum. At the first contact, participants meet with their assigned ETAU clinician and are given information about PPD, a brief clinical mental health assessment, and a referral for treatment if warranted or requested; the second session is a follow-up mental health clinical assessment with the study clinician and a referral for treatment if warranted or requested; at the third session, participants meet again with their study clinician and receive a mental health assessment, review relevant psychoeducation on PPD and are referred to treatment when appropriate.

    Also known as: ETAU

05

What researchers measure

Primary outcomes

  1. Score on the Edinburgh Postnatal Depression Scale (EPDS)

    Maternal mood: Postpartum Depression Symptoms will be measured by Edinburgh Postnatal Depression Scale (EPDS). The EPDS is a 10-item questionnaire that was developed to identify women who have postpartum depression. Items of the scale correspond to various clinical depression symptoms, such as guilt feeling, sleep disturbance, low energy, anhedonia, and suicidal ideation. Overall assessment is done by total score, which is determined by adding together the scores for each of the 10 items. Scores range from 0 to 30, with higher scores indicate more depressive symptoms (worse outcome).

    Time frame: Baseline, 6 weeks, 12 weeks, and 16 weeks postpartum

  2. Score on the Pittsburgh Sleep Quality Index (PSQI)

    Maternal perception of sleep quality: The Pittsburgh Sleep Quality Index (PSQI) is a self-rated questionnaire that assesses sleep quality and disturbances over a 1-month time interval. A total of 19 individual items generate 7 "component" scores: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. Scores range from 0 to 21, where lower scores indicate a healthier sleep quality (better outcome).

    Time frame: Baseline, 6 weeks, 12 weeks, and 16 weeks postpartum

  3. Score on HRSD-24

    The Hamilton Rating Scale for Depression (HRSD), also called the Hamilton Depression Rating Scale (HDRS), sometimes also abbreviated as HAM-D, is a multiple-item questionnaire used to provide an indication of depression, and as a guide to evaluate recovery. The patient is rated on 24 items scored either on a 3-point (0-2) or 5-point (0-4) Likert-type scale. Total scores range from 0 to 74 with a lower score indicating a better outcome.

    Time frame: Baseline, 6 weeks, 12 weeks, and 16 weeks postpartum

  4. Score on the PHQ-9

    The nine-item Patient Health Questionnaire (PHQ-9) is a depressive symptom scale and diagnostic tool introduced in 2001 to screen adult patients in primary care settings. The instrument assesses for the presence and severity of depressive symptoms and a possible depressive disorder. It is scored by simply adding up the individual items' scores. Scores range from 0 to 27 with a lower score indicating a better outcome.

    Time frame: Baseline, 6 weeks, 12 weeks, and 16 weeks postpartum

  5. Hamilton Anxiety Scale (HRSA)

    The scale consists of 14 items designed to assess the severity of a patient's anxiety. The patient is rated by on 14 items scored on a 5-point (0-4) Likert-type scale. Total scores range from 0 to 56 with a lower score indicating a better outcome.

    Time frame: Baseline, 6 weeks, 12 weeks, and 16 weeks postpartum

  6. Sleep Efficiency (SEact) of the Mothers

    Sleep Efficiency (SEact) was measured by an activity monitor worn by the participants continuously over 7 days. SEact is reported as a percent of time spent asleep during the total time spent in bed.

    Time frame: 28-32 weeks gestation (prenatal), 34-39 weeks gestation (prenatal), 6 weeks postpartum, 16 weeks postpartum

Secondary outcomes

  1. Total Nocturnal Sleep Duration - Brief Infant Sleep Questionnaire (BISQ)

    The BISQ is a parent-reported questionnaire on infants/toddler (0-29 months) sleep over 7 days

    Time frame: 6 weeks and 16 weeks postpartum

  2. Total Daytime Sleep Duration - Brief Infant Sleep Questionnaire (BISQ)

    The BISQ is a parent-reported questionnaire on infants/toddler (0-29 months) sleep over 7 days.

    Time frame: 6 weeks and 16 weeks postpartum

  3. Total Number of Instances of Waking up at Night - Brief Infant Sleep Questionnaire (BISQ)

    The BISQ is a parent-reported questionnaire on infants/toddler (0-29 months) sleep over 7 days.

    Time frame: 6 weeks and 16 weeks postpartum

  4. Total Settling Time to Fall Asleep for the Night - Brief Infant Sleep Questionnaire (BISQ)

    The BISQ is a parent-reported questionnaire on infants/toddler (0-29 months) sleep over 7 days.

    Time frame: 6 weeks and 16 weeks postpartum

  5. Daily Minutes of Infant Crying Over 4 Days

    Cry behavior will be measured by The Baby Day Diary, which is a 24-hour diary of infant and parental behavior for days. The number of minutes for the crying behavior is averaged over a span of 4 days, with a higher number indicating a worse outcome.

    Time frame: 6 weeks and 16 weeks postpartum

  6. Length of Longest Sleep at Night for Infants Over 4 Days

    Sleep behavior will be measured by The Baby Day Diary, which is a 24-hour diary of infant and parental behavior for days. The number of minutes of sleep is averaged over a span of 4 days. A higher number indicates a better outcome.

    Time frame: 6 weeks and 16 weeks postpartum

  7. Total Sleep Time (TSTact) in the Mothers

    TSTact was measured by an activity monitor worn by the participants continuously over 7 days.

    Time frame: 28-32 weeks gestation (prenatal), 34-39 weeks gestation (prenatal), 6 weeks postpartum, 16 weeks postpartum

Other outcomes

  1. Total Daily Minutes of Sleep Reported on the Self-Reported Sleep Log (Mother)

    Self-reported sleep time was recorded by participants each night over a span of 7 days.

    Time frame: 28-32 weeks gestation (prenatal), 34-39 weeks gestation (prenatal), 6 weeks postpartum, 16 weeks postpartum

06

Results

Posted Sep 26, 2025

Participant flow

Participant flow — Overall Study
MilestonePractical Resources for Effective Postpartum (PREPP)Enhanced Treatment as Usual
Started8887
6-week postpartum session6966
12-week postpartum session5252
16-week postpartum session5757
Completed5757
Not completed3130

Outcome measures

PrimaryScore on the Edinburgh Postnatal Depression Scale (EPDS)

Maternal mood: Postpartum Depression Symptoms will be measured by Edinburgh Postnatal Depression Scale (EPDS). The EPDS is a 10-item questionnaire that was developed to identify women who have postpartum depression. Items of the scale correspond to various clinical depression symptoms, such as guilt feeling, sleep disturbance, low energy, anhedonia, and suicidal ideation. Overall assessment is done by total score, which is determined by adding together the scores for each of the 10 items. Scores range from 0 to 30, with higher scores indicate more depressive symptoms (worse outcome).

Time frame:
Baseline, 6 weeks, 12 weeks, and 16 weeks postpartum
Reported as:
Mean · score on a scale
Score on the Edinburgh Postnatal Depression Scale (EPDS)
score on a scalePractical Resources for Effective Postpartum (PREPP)Enhanced Treatment as Usual
Baseline5.04 ± 0.494.36 ± 3.51
6 week4.43 ± 0.464.04 ± 0.42
12 week3.51 ± 0.393.74 ± 0.42
16 week3.69 ± 0.414.04 ± 0.44
PrimaryScore on the Pittsburgh Sleep Quality Index (PSQI)

Maternal perception of sleep quality: The Pittsburgh Sleep Quality Index (PSQI) is a self-rated questionnaire that assesses sleep quality and disturbances over a 1-month time interval. A total of 19 individual items generate 7 "component" scores: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. Scores range from 0 to 21, where lower scores indicate a healthier sleep quality (better outcome).

Time frame:
Baseline, 6 weeks, 12 weeks, and 16 weeks postpartum
Reported as:
Mean · score on a scale
Score on the Pittsburgh Sleep Quality Index (PSQI)
score on a scalePractical Resources for Effective Postpartum (PREPP)Enhanced Treatment as Usual
Baseline7.01 ± 0.376.55 ± 0.35
6 week7.21 ± 0.438.16 ± 0.47
12 week5.73 ± 0.406.48 ± 0.44
16 week5.88 ± 0.396.06 ± 0.40
PrimaryScore on HRSD-24

The Hamilton Rating Scale for Depression (HRSD), also called the Hamilton Depression Rating Scale (HDRS), sometimes also abbreviated as HAM-D, is a multiple-item questionnaire used to provide an indication of depression, and as a guide to evaluate recovery. The patient is rated on 24 items scored either on a 3-point (0-2) or 5-point (0-4) Likert-type scale. Total scores range from 0 to 74 with a lower score indicating a better outcome.

Time frame:
Baseline, 6 weeks, 12 weeks, and 16 weeks postpartum
Reported as:
Mean · score on a scale
Score on HRSD-24
score on a scalePractical Resources for Effective Postpartum (PREPP)Enhanced Treatment as Usual
Baseline4.09 ± 0.393.16 ± 0.32
6 week3.23 ± 0.342.99 ± 0.32
12 week2.99 ± 0.343.31 ± 0.37
16 week2.74 ± 0.312.73 ± 0.31
PrimaryScore on the PHQ-9

The nine-item Patient Health Questionnaire (PHQ-9) is a depressive symptom scale and diagnostic tool introduced in 2001 to screen adult patients in primary care settings. The instrument assesses for the presence and severity of depressive symptoms and a possible depressive disorder. It is scored by simply adding up the individual items' scores. Scores range from 0 to 27 with a lower score indicating a better outcome.

Time frame:
Baseline, 6 weeks, 12 weeks, and 16 weeks postpartum
Reported as:
Mean · score on a scale
Score on the PHQ-9
score on a scalePractical Resources for Effective Postpartum (PREPP)Enhanced Treatment as Usual
Baseline6.36 ± 0.495.64 ± 0.45
6 week5.21 ± 0.445.42 ± 0.46
12 week4.13 ± 0.395.19 ± 0.47
16 week4.50 ± 0.414.08 ± 0.38
PrimaryHamilton Anxiety Scale (HRSA)

The scale consists of 14 items designed to assess the severity of a patient's anxiety. The patient is rated by on 14 items scored on a 5-point (0-4) Likert-type scale. Total scores range from 0 to 56 with a lower score indicating a better outcome.

Time frame:
Baseline, 6 weeks, 12 weeks, and 16 weeks postpartum
Reported as:
Mean · score on a scale
Hamilton Anxiety Scale (HRSA)
score on a scalePractical Resources for Effective Postpartum (PREPP)Enhanced Treatment as Usual
Baseline4.09 ± 0.413.63 ± 0.37
6 week3.01 ± 0.333.09 ± 0.34
12 week3.01 ± 0.353.30 ± 0.38
16 week2.93 ± 0.342.94 ± 0.34
PrimarySleep Efficiency (SEact) of the Mothers

Sleep Efficiency (SEact) was measured by an activity monitor worn by the participants continuously over 7 days. SEact is reported as a percent of time spent asleep during the total time spent in bed.

Time frame:
28-32 weeks gestation (prenatal), 34-39 weeks gestation (prenatal), 6 weeks postpartum, 16 weeks postpartum
Reported as:
Mean · percent
Sleep Efficiency (SEact) of the Mothers
percentPractical Resources for Effective Postpartum (PREPP)Enhanced Treatment as Usual
28-32 weeks gestation71.90 ± 21.2573.44 ± 25.21
34-39 weeks gestation74.00 ± 22.6771.28 ± 24.31
6 week postpartum65.32 ± 25.5571.14 ± 20.78
16 week postpartum69.25 ± 22.2476.74 ± 17.91
SecondaryTotal Nocturnal Sleep Duration - Brief Infant Sleep Questionnaire (BISQ)

The BISQ is a parent-reported questionnaire on infants/toddler (0-29 months) sleep over 7 days

Time frame:
6 weeks and 16 weeks postpartum
Reported as:
Mean · hours
Total Nocturnal Sleep Duration - Brief Infant Sleep Questionnaire (BISQ)
hoursPractical Resources for Effective Postpartum (PREPP)Enhanced Treatment as Usual
6 weeks7.27 ± 2.087.26 ± 1.97
16 weeks8.24 ± 2.128.30 ± 1.79
SecondaryTotal Daytime Sleep Duration - Brief Infant Sleep Questionnaire (BISQ)

The BISQ is a parent-reported questionnaire on infants/toddler (0-29 months) sleep over 7 days.

Time frame:
6 weeks and 16 weeks postpartum
Reported as:
Mean · hours
Total Daytime Sleep Duration - Brief Infant Sleep Questionnaire (BISQ)
hoursPractical Resources for Effective Postpartum (PREPP)Enhanced Treatment as Usual
6 weeks6.17 ± 2.666.65 ± 2.47
16 weeks4.84 ± 2.454.50 ± 1.87
SecondaryTotal Number of Instances of Waking up at Night - Brief Infant Sleep Questionnaire (BISQ)

The BISQ is a parent-reported questionnaire on infants/toddler (0-29 months) sleep over 7 days.

Time frame:
6 weeks and 16 weeks postpartum
Reported as:
Mean · awakenings
Total Number of Instances of Waking up at Night - Brief Infant Sleep Questionnaire (BISQ)
awakeningsPractical Resources for Effective Postpartum (PREPP)Enhanced Treatment as Usual
6 weeks2.61 ± 1.052.71 ± 1.17
16 weeks1.77 ± 1.081.85 ± 1.26
SecondaryTotal Settling Time to Fall Asleep for the Night - Brief Infant Sleep Questionnaire (BISQ)

The BISQ is a parent-reported questionnaire on infants/toddler (0-29 months) sleep over 7 days.

Time frame:
6 weeks and 16 weeks postpartum
Reported as:
Mean · minutes
Total Settling Time to Fall Asleep for the Night - Brief Infant Sleep Questionnaire (BISQ)
minutesPractical Resources for Effective Postpartum (PREPP)Enhanced Treatment as Usual
6 weeks41.23 ± 35.0431.35 ± 20.16
16 weeks31.21 ± 22.5032.23 ± 30.07
SecondaryDaily Minutes of Infant Crying Over 4 Days

Cry behavior will be measured by The Baby Day Diary, which is a 24-hour diary of infant and parental behavior for days. The number of minutes for the crying behavior is averaged over a span of 4 days, with a higher number indicating a worse outcome.

Time frame:
6 weeks and 16 weeks postpartum
Reported as:
Mean · minutes per day
Daily Minutes of Infant Crying Over 4 Days
minutes per dayPractical Resources for Effective Postpartum (PREPP)Enhanced Treatment as Usual
6 weeks164.72 ± 81.32117.35 ± 72.46
16 weeks98.75 ± 66.58101.25 ± 48.23
SecondaryLength of Longest Sleep at Night for Infants Over 4 Days

Sleep behavior will be measured by The Baby Day Diary, which is a 24-hour diary of infant and parental behavior for days. The number of minutes of sleep is averaged over a span of 4 days. A higher number indicates a better outcome.

Time frame:
6 weeks and 16 weeks postpartum
Reported as:
Mean · minutes
Length of Longest Sleep at Night for Infants Over 4 Days
minutesPractical Resources for Effective Postpartum (PREPP)Enhanced Treatment as Usual
6 weeks249.52 ± 81.04238.24 ± 106.78
16 weeks291.52 ± 71.91277.67 ± 74.33
SecondaryTotal Sleep Time (TSTact) in the Mothers

TSTact was measured by an activity monitor worn by the participants continuously over 7 days.

Time frame:
28-32 weeks gestation (prenatal), 34-39 weeks gestation (prenatal), 6 weeks postpartum, 16 weeks postpartum
Reported as:
Mean · minutes
Total Sleep Time (TSTact) in the Mothers
minutesPractical Resources for Effective Postpartum (PREPP)Enhanced Treatment as Usual
28-32 weeks gestation305.03 ± 163.77291.34 ± 180.48
34-39 weeks gestation329.17 ± 168.50274.50 ± 170.60
6 weeks postpartum273.89 ± 159.13249.66 ± 161.42
16 weeks postpartum282.90 ± 152.18286.00 ± 141.96
Other pre-specifiedTotal Daily Minutes of Sleep Reported on the Self-Reported Sleep Log (Mother)

Self-reported sleep time was recorded by participants each night over a span of 7 days.

Time frame:
28-32 weeks gestation (prenatal), 34-39 weeks gestation (prenatal), 6 weeks postpartum, 16 weeks postpartum
Reported as:
Mean · minutes per day
Total Daily Minutes of Sleep Reported on the Self-Reported Sleep Log (Mother)
minutes per dayPractical Resources for Effective Postpartum (PREPP)Enhanced Treatment as Usual
28-32 weeks gestation393.51 ± 72.90402.90 ± 78.21
34-39 weeks gestation394.25 ± 97.37390.10 ± 92.38
6 weeks postpartum370.01 ± 125.64336.02 ± 75.83
16 weeks postpartum408.90 ± 91.20381.45 ± 72.54

Adverse events

Collected over During each assessment session, from 20-29 weeks gestation to 16 weeks postpartum, approximately 21- 36 weeks of participation. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Practical Resources for Effective Postpartum (PREPP)0/88 (0%)0/88 (0%)0/88 (0%)
Enhanced Treatment as Usual0/87 (0%)0/87 (0%)0/87 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)Practical Resources for Effective Postpartum (PREPP)Enhanced Treatment as UsualTotal
Mean31.15 ± 5.5130.16 ± 6.830.66 ± 6.19
Sex: Female, Male
Sex: Female, Male(Participants)Practical Resources for Effective Postpartum (PREPP)Enhanced Treatment as UsualTotal
Female8887175
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Practical Resources for Effective Postpartum (PREPP)Enhanced Treatment as UsualTotal
Hispanic or Latino5454108
Not Hispanic or Latino343367
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Practical Resources for Effective Postpartum (PREPP)Enhanced Treatment as UsualTotal
American Indian or Alaska Native022
Asian347
Native Hawaiian or Other Pacific Islander101
Black or African American151126
White221537
More than one race7310
Unknown or Not Reported405292
Region of Enrollment
Region of Enrollment(participants)Practical Resources for Effective Postpartum (PREPP)Enhanced Treatment as UsualTotal
United States8887175
07

Study locations

1 site
  • New York State Psychiatric Institute
    New York, New York 10032, United States
08

References and documents

Study documents

  • Protocol and statistical analysis plan · Nov 12, 2024

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: Yes — De-identified data may be made available to other researchers.

Supporting information: Study protocol, Icf

09

Registry details

Key details

Study ID
NCT03283254
Lead sponsor
Columbia University
Collaborators
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Responsible party
Catherine Monk (Diana Vagelos Professor of Women's Mental Health (in Obstetrics and Gynecology and Psychiatry), Columbia University) — Principal investigator
First posted
Sep 14, 2017
Start date
Feb 12, 2018
Primary completion
Feb 28, 2024
Completion
Feb 28, 2024
Results posted
Sep 26, 2025
Last update
Sep 26, 2025

Study contacts

Catherine Monk, PhD
principal investigator · Columbia University
Elizabeth Werner, PhD
study director · Columbia University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion